Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Archive — April 2026
Page 5 of 5 of this archive, newest first.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Denmark pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What PeptideMeter is able to certify about a sealed vial, and what it is not
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
From vial to bench: what is recorded and what is assumed
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
What a 7% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
PeptideMeter result on a Guangzhou orforglipron lot lands 1.7 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
From the floor in Xi'an: 11 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 26-day notice: how a compounding wind-down works in the United Kingdom
The document is four pages. Three of them are about dates.